Universal Multi–Mill Glovebox - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Universal Multi-Mill Glovebox

The Universal Multiple Mill Glovebox for Multiple Mill Systems is part of the Contained Powder Handling product range from original pioneers of high containment technology Powder Systems Limited. PSL’s multiple mill isolator can accommodate different mills in a single glovebox.

A specially designed L-shape window glovebox for inert milling provides product and operator protection, with good access for changing, stripping and cleaning mills within the glovebox. PSL’s Milling Isolator features a lift-up window  for enhanced viewing and ergonomics.

Contained milling process gives an enhanced operator viewing, ergonomics and an assured explosion protection system.

The Universal Multiple Mill Glovebox offers the advantage of a nitrogen-purged environment, nanogram containment, a small area to clean and better control over cross-contamination.

PSL’s universal Milling Isolator is the optimum solution when multiple mills, micronizers or air jet mills are required for a single product or process. Suitable from lab scale to complete facility requirements for manufacturing formulation.

PSL has extensive global experience in contained milling and is an original pioneer of high containment technology. Established for 25 years, PSL provide a full range of high containment solutions for applications including: dispensing and sampling, charging, drum filling, off-loading, sieving and tray drying.

Company name:  Powder Systems Limited

Website: www.powdersystems.com/milling.html         

E-mail: marketing@powdersystems.com

 

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
FindPharma Custom Search

Click here